RankAlpha logo
Back to Rankings

REVB

Revelation BiosciencesB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Confirmed TITAN enrollment could reduce execution uncertainty around Gemini's acute-kidney-injury program. The CRO appointment is progress, not evidence of enrollment or efficacy.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Low coverage and sector-and-size-only peer matches limit valuation confidence.
Momentum
86
Value
57
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.40 · Bull $5.50 · Bear $1.60Analysis 2026-10-26; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-26 • Vendor: Data Vendor v1
Scores
As of 2026-10-26 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-26 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-26

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-26. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $124.25
Why
Momentum86 · Δ7d -
Value57 · Δ7d +0.0
Sentiment50 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Value remains the lead driver in the composite, 7D delta +0.0.

Contradictions & invalidation

  • • Low coverage and sector-and-size-only peer matches limit valuation confidence.
  • • Management's June 30 cash runway estimate extends only through the first quarter of 2027, raising financing and dilution risk. [#SEC-8K-2026-08-06]
  • • Second-quarter operating cash use exceeded the year-earlier period, while management estimated funding only through the first quarter of 2027.

Catalyst clock

2026-10-20

Post-split Nasdaq compliance

Lead driver: Value · See fundamentals
Momentum
86
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.5
Sentiment
50
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 86.3 / Value 57.1 / Sentiment 50.5

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-26. Scenario method

B+
Bull case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$3.40
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.60
Analysis reference price unavailable
Analysis 2026-10-26 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-26
Market Cap
$2.01M
Beta
-0.11
Shares Out
569.06K
P/E (TTM) · Derived
-0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.66
Rev YoY
-
EPS YoY
-96.9%
Gross Margin
-
Op Margin
-
Net Debt
-$9.95M
Current Ratio
6.21
As of 2026-10-26 • Updated nightlySource: Internal modelMethods & Data